Triple Therapy with Doxorubicin, Imatinib and Tamoxifen in Recurrence Desmoids Tumor Associated with Pregnancy: Case Report and Literature Review
| Author | Mozaffar Aznab | en |
| Orcid | Mozaffar Aznab [0000-0002-1498-5205] | en |
| Issued Date | 2017-01-31 | en |
| Abstract | Introduction: Desmoid tumors, also known as aggressive fibromatosis, grow slowly but are locally aggressive. The therapy strategy consists of surgery, and radiation. Systemic therapy with non-steroidal anti-inflammatory drugs, antiestrogen compounds, cytotoxic chemotherapy and protein kinase inhibitors are recommended for recurrence, unresectable, advanced disease and failure to response to primary treatment. Case Presentation: We report on a 35-year-old female patient with advanced fibromatosis of the soft tissue of neck who has been treated with triple therapy including 8 cycles of Doxorubicin, Tamoxifen daily, and Imatinib daily. Tumor response was evaluated clinically and by enhanced CT SCAN imaging. Conclusions: 90% reduction in tumor size occurred after 6 months of treatment. The response continued and after 8 courses of doxorobicine treatment switched to triple therapy with imatinib , tamoifen and celexocib | en |
| DOI | https://doi.org/10.17795/ijcp-5476 | en |
| Keyword | Desmoid Tumor | en |
| Keyword | Pregnancy | en |
| Keyword | Triple therapy | en |
| Publisher | Brieflands | en |
| Title | Triple Therapy with Doxorubicin, Imatinib and Tamoxifen in Recurrence Desmoids Tumor Associated with Pregnancy: Case Report and Literature Review | en |
| Type | Case Report | en |